JAMP-ASA 81MG EC TABLET (ENTERIC-COATED)
Country: Canada
Language: English
Source: Health Canada
Summary of Product characteristics
(SPC)
01-09-2022
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
ACETYLSALICYLIC ACID
Available from:
VITA HEALTH PRODUCTS INC
ATC code:
B01AC06
INN (International Name):
ACETYLSALICYLIC ACID
Dosage:
81MG
Pharmaceutical form:
TABLET (ENTERIC-COATED)
Composition:
ACETYLSALICYLIC ACID 81MG
Administration route:
ORAL
Units in package:
1000
Prescription type:
OTC
Therapeutic area:
SALICYLATES
Product summary:
Active ingredient group (AIG) number: 0101169013; AHFS:
Authorization status:
APPROVED
Authorization date:
2014-07-30
Summary of Product characteristics
Jamp - ASA 81 mg EC Page 1 of 46
PRODUCT MONOGRAPH
JAMP - ASA 81 MG EC
Acetylsalicylic
Acid Delayed Release Tablets
81 mg
USP
Platelet aggregation inhibitor
Vita Health Products Inc.
150 Beghin Avenue
Winnipeg,
MB
Canada R2J 3W2
Control Number: 264031
Date of Preparation:
February 3, 2011
Date of Revision :
September 1, 2022
Jamp - ASA 81 mg EC Page 2 of 46
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................... 3
SUMMARY PRODUCT INFORMATION
..............................................................................
3
INDICATIONS AND CLINICAL USE
...................................................................................
3
CONTRAINDICATIONS........................................................................................................
4
WARNINGS AND PRECAUTIONS
.......................................................................................
4
ADVERSE REACTIONS
........................................................................................................
7
DRUG INTERACTIONS
........................................................................................................
7
DOSAGE AND ADMINISTRATION
.....................................................................................
9
OVERDOSAGE.....................................................................................................................10
ACTION AND CLINICAL PHARMACOLOGY
....................................................................11
STORAGE AND STABILITY
...............................................................................................13
DOSAGE FORMS, COMPOSITION AND
PACKAGING......................................................13
PART II: SCIENTIFIC INFORMATION
.........................................................................
14
PHARMACEUTICAL INFORMATION
................................................................................14
CLINICAL
TRIALS................................................................
Read the complete document
